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ns.org/licenses/by-nc-Abstract Introduction/objectives: Asymmetric dimethylarginine (ADMA) is a car-
diac biomarker in humans, symmetric dimethylarginine (SDMA) a renal biomarker
in humans, cats, and dogs. The purpose of this prospective study was to investigate
if measuring serum ADMA and SDMA concentrations via ELISA allows detection of
cardiac disease in horses in a routine laboratory setting. In this context, reference
values in horses were established.
Animals, materials, and methods: Seventy-eight horses with no known medical his-
tory were compared to 23 horses with confirmed structural cardiac disease with/or
without arrhythmias. Horses underwent physical examination, electrocardiography,
echocardiography and venous blood sampling and were staged based on the sever-
ity of cardiac disease from 0 to II. Asymmetric dimethylarginine and SDMA were
measured via ELISA and crosschecked using liquid chromatograph triple quadrupole
mass spectrometry. Reference intervals with 90th percent confidence intervals
were evaluated and standard software was used to test for significant differences
in ADMA, SDMA, and the L-arginine/ADMA ratio between groups.
Results: The reference ranges were 1.7e3.8 mmol/L and 0.3e0.8 mmol/L for ADMAof Veterinary Cardiology is the emphasis of additional web-based materials permitting the
s. These materials can be viewed (by those readers with subscription access) by going to . The
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SDMA symmetric dimethand SDMA, respectively. Serum ADMA was higher in horses with heart disease com-
pared to healthy horses (p < 0.01) and highest in horses with stage II heart disease
(p ¼ 0.02). The L-Arginine/ADMA ratio was significantly higher in healthy animals
than those with cardiac disease (p ¼ 0.001).
Conclusions: Reference values for serum ADMA and SDMA using ELISA methods are
presented in horses. This study confirms the association between heart disease
and increased serum ADMA concentration as well as a decreased L-Arginine/ADMA
ratio in horses.
ª 2020 The Authors. Published by Elsevier B.V. This is an open access article under




Asymmetric dimethylarginine (ADMA) is a natu-
rally occurring modified amino acid that inhibits
the production of nitric oxide (NO), a key regu-
lator of vascular tone [1e3]. Nitric oxide is pro-
duced from L-arginine as the natural substrate of
NO synthase [2e4]. However, NO synthesis can be
reduced by at least two of three different deriv-
atives of L-arginine: symmetric dimethylarginine
(SDMA), ADMA, and possibly also by monomethyl-
L-arginine [4e6]. All three are generated via
intracellular methylation of arginine via protein
arginine methyltransferases and released into
plasma in exchange for arginine and other cati-
onic amino acids [4e7].
An increasing number of studies have linked
elevated concentrations of circulating ADMA to
cardiovascular disease [3,8e14]. Furthermore, a
growing number of studies showed a strong link
between the L-arginine/ADMA ratio and the
severity of chronic heart failure in humans
[15e17], raising the question whether this ratio
might also be useful for identifying cardiovascular
risk in equines.
After intracellular uptake by major organs such
as the liver, brain, or kidney over 80% of circu-
lating ADMA is eliminated through enzymatic
degradation by the enzyme dimethylarginine
dimethylaminohydrolase [18e20]. Symmetric
dimethylarginine is primarily eliminated throughrenal filtration and correlates with both meas-
ured and estimated glomerular filtration rate.
The importance of SDMA as an endogenous marker
of renal function in humans, cats, and dogs is
rising [19e24]. In dogs and cats, SDMA is used
both for early identification and monitoring of
decreased renal function in kidney disease
[21,22].
In contrast and despite promising potential,
research on the topic of SDMA and ADMA in car-
diac or renal disease in horses is currently lack-
ing. This is unfortunate since due to the species-
independent chemical structure of SDMA, ELISA
techniques developed for humans have emerged
as useful and cost-efficient screening tools in
veterinary sciences under practical clinical con-
ditions [21,22].
The purpose of this prospective study was to
investigate if measuring serum SDMA and ADMA
concentrations via ELISA in a routine laboratory
setting allows detection of cardiac disease in
horses. We hypothesized that ADMA serum con-
centration might be higher in horses with cardiac
disease compared to healthy horses. In this con-
text, reference values in horses were established.Animals, materials, and methods
The study was performed in compliance with
guidelines from the Ethical Committee and
European Union legislation. Permission to con-
duct the study was attained from national
authorities (license number 0206/18). Horses
were recruited either at national or international
horse competitions or by a public call for study
participation.
Horses without cardiac disease served as refer-
ence group. Inclusion criteria for the healthy group
were no known history or clinical signs of cardiac
disease or any other diseases. Cardiovascular
Symmetric and asymmetric dimethylarginine 45disease was excluded based on echocardiography
and electrocardiography. Horses with a physio-
logical atrioventricular block were included in the
healthy group, provided that the block dis-
appeared during physical activity. Horses with
more than trivial (physiological) valve regur-
gitation on colou flow Doppler echocardiography or
a pathological arrhythmia on electrocardiogram
were excluded from the healthy group. Car-
diovascular disease was further excluded based on
venous blood sampling for cardiac biomarkers
(cardiac troponin I, lactate dehydrogenase, a-
hydoxybutyrate dehydrogenase). For exclusion of
renal disease creatinine and urea were measured.
For horses to be included within the reference
group, cardiac troponin I, lactate dehydrogenase,
a-hydoxybutyrate dehydrogenase, creatinine, and
urea had to be within the reference ranges. Only
horses with confirmed heart disease were included
in the second group of horses with cardiac disease.
Animals with the presence of any other disease
were excluded from the study.
In addition to obtaining the medical history for
each animal, all animals were subjected to a
general physical examination, echocardiography,
electrocardiography, and venous blood sampling
for cardiac and renal biomarkers. Heart rate,
respiratory rate, rectal temperature, pulse qual-
ity, mucous membranes, and heart sounds were
assessed.Echocardiography and
electrocardiography
Transthoracic echocardiography was performed
by means of a portable ultrasound unitd with a
phased array transducer and simultaneous elec-
trocardiogram recording. A single observer
assessed cardiac structures, valvular com-
petence, chamber dimensions and the diameters
of the aorta, the pulmonary artery, and left
ventricular systolic function by routine two-
dimensional, motion mode, and color flow Dop-
pler echocardiographye.
Electrocardiographic recordings were obtained
with a Holter recording systemf with two channelsd Vivid I, GE Healthcare GmbH, Torgauer Str. 12e15, Berlin,
Germany.
e EchoPAC, clinical workstation software, GE Healthcare
GmbH, Torgauer Str. 12e15, Berlin, Germany.
f Televet-100 electrocardiogram device from Engel Engineer-
ing Service GmbH, Heusenstamm, Germany.and bipolar leads. Electrodes were secured with
adhesive foam patches.Grading of cardiac disease
Severity of cardiac disease was graded using a
modification of the system proposed by Gehlen
2010 [25]. Horses in stage 0 were healthy and
horses in stage I had mild to moderate valvular
incompetence and cardiac dimensions within the
reference range. Horses in stage II had increased
cardiac dimensions due to severe valvular incom-
petence, in some cases with concomitant addi-
tional arrhythmia or increased cardiac troponin I
and pericardial effusion. The valvular incom-
petence was graded according to the quantifica-
tion methods defined by Gehlen et al. [25,26],
Stadler et al. [27], Vahanian et al. [28] and Young
et al. [29].Laboratory analysis
Blood samples were obtained from the jugular vein
via 18-gauge needles in all horses. Samples were
collected in 6 mL EDTA tubes and 20 mL serum
separator tubes. Serum was separated by cen-
trifugation at a force of 1800g for 10 min after
clotting was completed. EDTA-plasma was also
separated by centrifugation at a force of 1800g
for 10 min. Serum and EDTA-plasma were trans-
ferred into 2 mL cryotubes and frozen on dry ice
until storage at 80C. Serum and EDTA-plasma
were sent on dry ice for analysis to different lab-
oratories. Total storage time was 8 months at
80C. Lactate dehydrogenase, a-hydoxybutyrate
dehydrogenase, creatinine, and urea were meas-
ured with ELISA technology with conventional
methods from serum samplesg. Cardiac troponin I
was determined in serum by an immunoassay
systemh.
Symmetric dimethylarginine and asymmetric
dimethylarginine were measured in serum samples
in duplicate with commercial human ELISAg Analyses of lactate dehydrogenase, a-hydoxybutyrate
dehydrogenase, creatinine, and urea were run by Laboklin
GmbH & CoKG with an analyzer from Bio Aim Scientific Inc.,
Steubenstrabe 4, 97,688 Bad Kissingen, Germany.
h Analysis of cardiac troponin I was run by Laboklin GmbH &
CoKG with Immulite 2000XPi Siemens, Steubenstrabe 4, 97,688
Bad Kissingen, Germany.
46 A. Ertelt et al.technologyi. The average of the duplicate deter-
minations was used.
Ten values, six of the highest measured values
from the group with cardiac disease and four val-
ues within the medium range measured in the
control group, were crosschecked using liquid
chromatograph triple quadrupole mass spectrom-
etry (LC-MS/MS)j.
For L-arginine analysis 400 mL EDTA plasma,
400 mL sample dilution buffer (including standard
norleucine 100 nmol/mL), and 200 mL precipitation
solution for the deproteinization were stored at
4C for 20 min. The suspension was centrifuged at
a force of 13,150g for 5 min and the supernatant
subsequently filtered with a membraspin filter at a
force of 13,150g for 5 min. L-arginine was ana-
lysed by the amino acid analyser Aracusk. Inte-
gration and calculation of the analysis were
performed via aminoPeak softwarek.Statistics
Reference intervals were determined from 78
healthy horses for SDMA and ADMA. Data were
evaluated according to Principles of Quality
Assurance and Standards for Veterinary Clinical
Pathology guidelines and calculated using the
program Reference Value Advisor [30]. Except for
SDMA, data were not normally distributed (Ander-
son-Darling test). The instructions of the Interna-
tional Federation of Clinical ChemistrydClinical
and Laboratory Standards Institute C28-A3 guide-
lines were followed in order to calculate non-
parametric 90% reference intervals using bootstrap
methods [31]. The 95% reference intervals were
calculated by nonparametric methods, and then,
the 90% confidence intervals about the lower and
upper limits of the reference interval were
calculated.
Statistical Package for the Social Sciences ver-
sion 25 was used for all statistical analyses
described in the following. Differences between
horses with and without cardiac disease regarding
ADMA, SDMA, and L-arginine/ADMA ratio were
investigated using the t-test (for SDMA) and thei Analyses of ADMA and SDMA via Fast ELISA were run by DLD
Gesellschaft für Diagnostika und medizinische Geräte mbH,
Adlerhorst 15, 22,459 Hamburg, Germany.
j Analyses of ADMA and SDMA via LC - MS/MS were run by
Medizinisches Labor Bremen GmbH, Haferwende 12, 28,357
Bremen, Germany.
k Analysis of L-arginine was run by MembraPure, Gesellschaft
für Membrantechnik mbH, Wolfgang Küntscher Str. 14, 16,761
Hennigsdorf/Berlin, Germany.Mann-Whitney U test (two groups, healthy (stage
0) and horses in stage I and II) or Kruskal-Wallis test
(comparison of healthy horses (stage 0), horses
stage I to II), as appropriate. p-values < 0.05 were
regarded as statistically significant.
Lin’s Concordance Coefficient was calculated to
assess agreement between ten laboratory ADMA
and SDMA values estimated with the ELISAi and the
reference method LC-MS/MSj. Since some ADMA
samples ran far out of the human reference range
for the LC-MS/MSj method, samples were con-
firmed once again after dilution.Results
The study population involved 78 healthy horses
and 23 horses with confirmed cardiac disease.
The study population of healthy horses con-
sisted of animals without known clinical disease,
aged between 4 and 21 years (average: 11.9 years,
median: 12 years). Animals weighed between 285
and 575 kg (average: 417 kg, median 410 kg).
All horses in the group exercised regularly and
most horses were used for endurance sport
(n ¼ 66). Horses originated from diverse locations
(Germany, Switzerland, Belgium, Italy, Austria,
Sweden, Norway, Portugal, Croatia, the Nether-
lands, United Kingdom, Algeria, Australia, Chile,
Uruguay, Columbia, Brazil, Ecuador, USA, Malay-
sia, Thailand, South Africa, and Bahrain). Breeds
included Arabian Thoroughbred (n ¼ 34), Arabian
Partbred (n ¼ 5), Shagya Arabian (n ¼ 4), Anglo-
Arabian (n ¼ 7), German Warmblood (n ¼ 3),
Standardbred (n ¼ 5), German Riding Pony (n ¼ 4),
Haflinger crossbreed (n ¼ 1), Pinto (n ¼ 1), Appa-
loosa (n ¼ 1), Arabian Akhal-Teke crossbreed
(n ¼ 1), Karbarda (n ¼ 1), and unknown (n ¼ 11).
There were 43 geldings, one stallion, and 34
mares.
Horses in the group with cardiac disease
(n ¼ 23) were between 2 and 29 years of age
(average: 15.8 years, median: 15 years) and
weighed between 240 and 750 kg (average 536 kg,
median 580 kg). All horses came from Germany.
Breeds consisted of German Warmblood (n ¼ 14),
Standardbred (n ¼ 2), German Riding Pony (n ¼ 2),
Arabian Thoroughbred (n ¼ 1) Appaloosa (n ¼ 1),
American Quarter Horse (n ¼ 1), Pinto (n ¼ 1),
Trakehner (n ¼ 1). The group included 13 geldings,
three stallions, and seven mares. One horse that
initially presented as healthy was excluded from
the study, since it had a heart murmur 3/6 and
more than trivial aortic valve regurgitation on
color flow Doppler echocardiography.
Table 1 Reference range (90th percent confidence interval) in mmol/L for asymmetric dimethylarginine (ADMA)
and symmetric dimethylarginine (SDMA) in healthy animals. Horses with cardiac disease in stage I and II, with
median and average ADMA (mmol/L) concentration. An asterisk (*) indicates data are normally distributed and a
section sign (x) indicates data are not normally distributed. Values with different superscripts (a, b) are sig-
nificantly different (p < 0.005). ADMA: asymmetric dimethylarginine; SDMA: symmetric dimethylarginine.



















I 0.518  0.092a 2.73 (2.50, 3.19)a,b 15
II 0.584  0.055a 3.19 (3.00, 3.57)b 7
Symmetric and asymmetric dimethylarginine 47Reference values for ADMA and SDMA were
determined in 78 healthy horses (Table 1). Lin’s
Concordance Coefficient revealed an excellent
test agreement between the ELISAi and the refer-
ence method (LC-MS/MSj) with 0.91 for ADMA and
0.94 for SDMA.
Of the horses with cardiac disease, 14 were in
stage I and 9 in stage II (Table 1). The values of
ADMA and cardiac troponin I as well as the clinical
symptoms (stage II) are given in Table A (available
in Supplemental Material online).
Apart from one horse with pericardial effusion
(horse stage II), cardiac troponin I was within theFig. 1 Boxplot showing serum asymmetric dimethy-
larginine (ADMA) concentration in mmol/L in healthy
horses and horses with cardiac disease. Asymmetric
dimethylarginine (mmol/L) showed significantly higher
values in horses with cardiac disease (stage II) compared
to healthy animals. The circles (⁰) represent outliers
between 1.5 and 3.0 times the interquartile range (IQR).
The asterisk (*) indicates p ¼ 0.003. ADMA: asymmetric
dimethylarginine.reference range (<0.03 ng/mL) (Table A, available
in Supplemental Material online).
The values of (normally distributed) SDMA data
did not differ significantly between healthy horses
and horses with cardiac disease (p ¼ 0.6), but the
values of ADMA differed significantly, with horses
suffering from cardiac disease having higher values
than healthy animals (p ¼ 0.003) (Fig. 1). Likewise,
no significant differences could be detected
between animals in stage 0 to II (p ¼ 0.2) for SDMA,
but ADMA showed significant differences between
the groups (p ¼ 0.007) with significantly higher
values in stage II horses compared to healthy ones
(adjusted p ¼ 0.02) (Table 1, Fig. 2). In addition,Fig. 2 Boxplot showing serum asymmetric dimethy-
larginine (ADMA) concentration in mmol/L in healthy
horses (stage 0) and horses with cardiac disease in stage
I and II. The circles (⁰) represent outliers. The asterisk (*)
indicates a significant difference between stage 0 and
stage II horses, p ¼ 0.007. ADMA: asymmetric
dimethylarginine.
Fig. 3 Boxplot showing the distribution of the ratio
between L-arginine (mmol/L) and asymmetric dimethy-
larginine (ADMA) (mmol/L) measured in healthy horses
and in horses with cardiac disease, showing a clear shift
of the distribution toward higher values in healthy ani-
mals. Differences between healthy horses and horses
with cardiac disease were statistically significant
(p ¼ 0.001, Mann-Whitney U test). The circles (⁰) rep-
resent outliers between 1.5 and 3.0 times the inter-
quartile range (IQR), the filled circle () indicates
outliers beyond 3.0 times IQR. The asterisk (*) indicates
p ¼ 0.001. ADMA: asymmetric dimethylarginine.
Fig. 4 Boxplot showing asymmetric dimethylarginine
(ADMA) serum concentration in mmol/L in horses with
mitral valve regurgitation (n ¼ 14, 8 in stage I and 6 in
stage II) and in healthy horses (without valve regur-
gitation) (n ¼ 78). Horses with mitral valve regurgitation
had significantly higher serum ADMA (mmol/L) concen-
trations than healthy horses. The circles (⁰) represent
outliers. The asterisk (*) indicates p ¼ 0.007. ADMA:
asymmetric dimethylarginine.
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nificantly higher in healthy horses than in horses
with cardiac disease (p ¼ 0.001) (Fig. 3).
Six horses suffered from atrial fibrillation, three
with and three without increased left atrial
diameter and area. Furthermore, one horse was
diagnosed with premature atrial complexes.
Horses with arrhythmia had an increased ADMA
serum concentration. Unfortunately, the data
structure did not make it possible to apply a mul-
tivariable analysis, which would have given further
information concerning other influence factors.
Horses with arrhythmia (p ¼ 0.01), mitral valve
regurgitation (p ¼ 0.007) (Fig. 4), and regur-
gitation of more than two valves (p ¼ 0.02) were
associated with a significantly higher ADMA.Discussion
Immunoassays have become the method of choice
for measurement of diagnostic markers in biouids
such as serum. In the present study, ADMA differed
significantly between healthy horses and horses
with cardiac disease. Animals with cardiac disease
had higher values than healthy animals. In contrast
to humans, the L-arginine/ADMA ratio in horses
showed no advantage compared to ADMA alone.
However, the finding that the L-arginine/ADMA
ratio is significantly higher in healthy horses than
in horses suffering from cardiac disease is an
important finding. Since ADMA competes with L-arginine for NO synthase, the bioavailability of NO
depends on the balance between the two. The L-
arginine/ADMA ratio is an indicator of NO bio-
availability and is therefore emerging as a poten-
tial marker of cardiovascular diseases in human
medicine [32]. In what way the L-arginine/ADMA
ratio affects horses and if it is a cause or the result
of the associated cardiac disease cannot be clari-
fied in the present study.
Despite our finding that ADMA differed sig-
nificantly between healthy animals and animals
with cardiac disease, the latter group rarely
exceeded the upper reference range of 3.8 mmol/L
(Table A, available in Supplemental Material
online). This is most likely a result of the limited
number of horses and the wide range of data
included in the study, leading to a high reference
range for the 90th percent confidence interval and
calling for the necessity of follow-up studies with a
greater number of animals.
In humans, ADMA measurement can be useful
for assessment of endothelial dysfunction as a
predictor of cardiovascular disease risk [3,6,8].
However, horses do not suffer from “typical”
human cardiovascular diseases, such as hyper-
tension, atherosclerosis, carotid artery intima-
media thickness, angina pectoris, and heart
attacks. However, atrial fibrillation is a disease
seen in both humans and horses.
A study conducted by Horowitz and coworkers
has shown that ADMA is elevated in human patients
with permanent atrial fibrillation [33]. Notably,
under conditions of NO synthase substrate (argi-
nine) depletion, ADMA leads to an “uncoupling” of
Symmetric and asymmetric dimethylarginine 49NO synthase so that electron transfer is shifted
from L-arginine to molecular oxygen, yielding the
radical superoxide anion. The role of endogenous
oxygen radicals in targeting DNA, proteins, lipids,
and other components of the cell has long been
known. Interestingly, studies on knockout mice
that lacked an enzyme responsible for mitochon-
drial radical superoxide anion removal exhibited
perinatal lethality due to cardiac dysfunction and
congestive heart failure [34]. However, it appears
likely that elevated levels of ADMA are the con-
sequence and not the cause of cardiac disease in
horses.
Horowitz and coworkers [33] mentioned that
the precise mechanism(s) whereby ADMA concen-
trations modulate outcomes in patients with
chronic atrial fibrillation remains somewhat puta-
tive. Dimethylarginine dimethylaminohydrolase,
the enzyme that plays a primary role in ADMA
metabolism is inhibited by oxidative stress [35] and
there is evidence that myeloperoxidase, an
enzyme of leukocyte origin that has been impli-
cated in the pathogenesis of atrial fibrillation, may
deactivate dimethylarginine dimethylaminohy-
drolase [36]. Determination of concentrations and
activity of both dimethylarginine dimethylamino-
hydrolase and myeloperoxidase might have helped
to further delineate the precise mechanism(s)
[36].
The immunoassay used in the current study has
been evaluated for SDMA in humans, cats, and dogs
and for ADMA in humans [21,22,37e40]. The
immunoassay showed adequate precision with
intra-and inter assay coecients of variation lower
than 15% [21,22,38,39]. Similar studies in horses
have not been published so far. The reference
values for equine SDMA determined in the present
study ranged between 0.3 and 0.8 mmol/L. Refer-
ence values for SDMA in humans, cats, and dogs
cited by DLD Diagnostika GmbHj are quite similar
(humans and cats: 0.30e0.75 mmol/L, dogs:
0.30e0.65 mmol/L) [39]. The equine reference
values for ADMA established in this study appear to
be noticeably higher than those found in humans
(0.40e0.75 mmol/L) [37,40]. This raised the ques-
tion why values in horses are so much higher or
whether possibly, these values were falsely high.
For this reason, we crosschecked six outliers and
four controls from the medium range using mass
spectrometry. In total, ten ADMA and SDMA values
were crosschecked using LC-MS/MSj and both
methods agreed very well. Notably, the ADMA
ELISA testi used in the present study has already
been assessed in humans and compared to the LC-
MS/MSj method [37,40], also showing good agree-
ment. Since ADMA and SDMA are well-defined,small compounds with a structure that is identical
in humans and equines, our finding that both
methods correlate well in horses is hardly
surprising.
Therefore, there appears to be other reasons
for the higher ADMA levels in horses. Notably, the
uptake of ADMA into the cytosol for degradation
occurs via an exchanger from the anion/cation
transporter family that requires intracellular
presence of dibasic amino acids such as arginine,
lysine, and ornithine as a substrate [41]. As a
herbivore, horses may well have a different amino
acid profile than carnivorous species [42e44],
possibly leading to a different profile.
The major limitation of the study is the small
sample size of 23 horses with cardiac disease that
lowered statistical power and might have impac-
ted the ability to detect differences between the
stages of cardiac disease, especially in stage II.
Furthermore, there is the possibility of a breed
effect on ADMA and SDMA concentration. There-
fore, the reference intervals might not be relevant
to other breeds of horses. Although samples from
the entire range were selected for comparison of
the ELISAi and LC-MS/MSj methods, sampling was
not random since six of the highest measured val-
ues were included. Strictly speaking, it is thus not
possible to generalize the results, although they
are in good agreement with previous studies
[37,39,40]. Furthermore, storage time of the
samples was 8 months and therefore values could
have decreased over time. No data on storage time
for ADMA or SDMA has been published to date. The
laboratory that carried out the analysisi has real
time data on storage time for at least 5 years from
32 quality control samples (human serum) that
were frozen at 23C. Over the past 5 years, these
quality control samples were measured seven
times and showed almost identical results. At
80C ADMA and SDMA should be at least as stable.Conclusions
In the present study, horses with cardiac disease
had significantly higher serum ADMA concentration
and a decreased L-arginine/ADMA ratio compared
to healthy horses. Although the physiological rea-
sons for higher serum ADMA concentration and a
decreased L-arginine/ADMA ratio in horses with
cardiac disease remain elusive, this study demon-
strates that ADMA is a promising biomarker not just
in humans, but also shows diagnostic potential in
identifying cardiac disease in horses under routine
conditions.
50 A. Ertelt et al.The manuscript is original. No part of the
manuscript has been published before, nor is any
part of it under consideration for publication in
another journal. There are no conflicts of interest
to disclose.Funding
The study was funded by Gesellschaft für Pferde-
medizin e.V., Hahnstrabe 70, 60528 Frankfurt
a.M., Germany, Register of association: VR 18845.Acknowledgements
We thank Dr. Rolf Lehmann (DLD Diagnostika
GmbH), Dr. Detlef Timmermann (MembraPure
GmbH) and Dr. Corinna Weber (Laboklin) for per-
forming analysis of symmetric dimethylarginine
and asymmetric dimethylarginine, L-arginine, tro-
ponin I, lactate dehydrogenase, alpha
hydroxybutyrate-dehydrogenase, creatinine, and
urea.Supplementary data
Supplementary data to this article can be
found online at .References
[1] Dias RG, Negrao CE, Krieger MH. Nitric oxide and the car-
diovascular system: cell activation, vascular reactivity and
genetic variant. Arq Bras Cardiol 2011;96:68e75.
[2] Tousoulis D, Kampoli AM, Tentolouris C, Papageorgiou N,
Stefanadis C. The role of nitric oxide on endothelial
function. Curr Vasc Pharmacol 2012;10:4e18.
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